Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has earned an average recommendation of “Moderate Buy” from the twenty-four brokerages that are covering the company, Marketbeat.com reports. Eight investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $269.32.
ALNY has been the topic of several recent analyst reports. Royal Bank of Canada boosted their price objective on shares of Alnylam Pharmaceuticals from $265.00 to $300.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. HC Wainwright restated a “buy” rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, June 24th. SVB Leerink increased their price target on Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the company a “market perform” rating in a research note on Tuesday, June 25th. The Goldman Sachs Group lifted their price objective on shares of Alnylam Pharmaceuticals from $174.00 to $198.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. Finally, JPMorgan Chase & Co. increased their price objective on shares of Alnylam Pharmaceuticals from $160.00 to $248.00 and gave the company a “neutral” rating in a research report on Wednesday, July 3rd.
Read Our Latest Analysis on ALNY
Insider Buying and Selling
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of ALNY. Allspring Global Investments Holdings LLC lifted its position in shares of Alnylam Pharmaceuticals by 572.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 143 shares during the period. Ashton Thomas Private Wealth LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $26,000. Altitude Crest Partners Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the 1st quarter valued at $30,000. Robeco Institutional Asset Management B.V. lifted its position in shares of Alnylam Pharmaceuticals by 155.7% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 12,513 shares during the period. Finally, GAMMA Investing LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $52,000. Institutional investors and hedge funds own 92.97% of the company’s stock.
Alnylam Pharmaceuticals Stock Performance
NASDAQ:ALNY opened at $262.89 on Thursday. Alnylam Pharmaceuticals has a 52-week low of $141.98 and a 52-week high of $274.93. The company has a market cap of $33.25 billion, a P/E ratio of -98.09 and a beta of 0.37. The stock’s 50-day simple moving average is $227.65 and its 200 day simple moving average is $179.08.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The company had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. The company’s revenue for the quarter was up 107.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($2.21) EPS. As a group, equities analysts predict that Alnylam Pharmaceuticals will post -3.99 earnings per share for the current fiscal year.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Read More
- Five stocks we like better than Alnylam Pharmaceuticals
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Brinker International’s Price Dip is an Appetizing Entry Point
- How to Invest in Biotech Stocks
- 3 Stocks That Could Beat the September Blues
- How to Read Stock Charts for Beginners
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.